On July 7, RemeGen (09995.HK) fell 5.01% in regular trading, trading at HK$83.6/share, with turnover of HK$295 million.

The broader biotech sector experienced widespread selling pressure, with AKESO down 3.34%, Innovent Biologics down 2.43%, BeiGene down 2.10%, and KEYMED Biosciences down 1.90%. The pullback comes after a period of exceptionally strong gains for RemeGen, with its A-share listing surging over 31% in the prior week alone, driven by catalysts including new drug approvals for Telitacicept in Sjogren's syndrome and IgA nephropathy, and innovative drug payment reform policies.

Additionally, 193 million restricted shares (34.16% of total equity) were unlocked on July 1, though selling pressure remains structurally limited as shareholders are prohibited from reducing holdings via centralized bidding or block trades due to the company's cash dividend not meeting regulatory requirements. The sector-wide retreat and profit-taking after the recent rally appear to be the primary near-term headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)